Sonmez HE, et al. - Authors presented their experiences of pediatric macrophage activation syndrome (MAS) patients treated with anakinra. They also reviewed previous studies reporting anakinra treatment in pediatric MAS patients related to systemic juvenile idiopathic arthritis (sJIA) or autoinflammatory diseases (AIDs). They included pediatric MAS patients due to sJIA or AIDs, followed up in the Pediatric Rheumatology Unit of Hacettepe University between January 2015 and January 2017 and treated with anakinra (anti-IL1). Findings suggested that all the patients included in this study reached remission, except for 2. The knowledge on the role of anakinra treatment in the management of MAS could be improved by this study and systematic literature review.